LONDON, July 5, 2018 /CNW/ - Senzer Ltd has announced that it intends to launch its inhaled cannabinoid portfolio of products later this year in the UK under a specials pharmaceutical licence. This would enable doctors to prescribe its inhaled cannabinoid products to cancer patients undergoing chemotherapy.
"Our delivery technology is a first of its kind - a respiratory delivery system that uses a breath-operated valve technology and delivers pharmaceutical grade cannabinoids rapidly into the bloodstream," Senzer CEO Alex Hearn has said.
With over 300,000 people across Europe and the US currently experiencing the most common side effects of chemotherapy, nausea and nerve pain, cannabinoids have long been identified as a highly promising supportive therapy alongside chemotherapy. Unfortunately oral delivery of cannabinoids has a limited therapeutic effect due to poor absorption, however doctors still regularly prescribe cannabinoid oral capsules for cancer patients under compassionate use schemes in Europe.
"We believe we have a unique respiratory delivery system for cannabinoids that can hopefully improve the quality of life for those going through extremely intense treatment," a spokesman for the company has said.
The first product available to be prescribed by doctors will be Cannafen®, a cannabidiol inhalation solution which the company has been developing since 2015. A further product containing dronabinol solution, called Candex® will be launched in the new year. Both products are subject to regulatory clearance.
Senzer's products containing cannabinoids are designed to offer fast and effective relief for nausea and breakthrough neuropathic pain, two common and poorly treated side effects of chemotherapy cancer treatments. These two conditions can have a significant impact on patient compliance, cancer treatment outcome and quality of life.
"We hope that this will be a new and meaningful treatment option available on prescription and increase the range of options for doctors and patients alike as they navigate their cancer care."
Further information can be found at http://www.senzer.com
SOURCE Senzer Limited